The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a “red flag” of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis).

Belmonte, M., Foa, A., Paolisso, P., Bergamaschi, L., Gallinoro, E., Polimeni, A., et al. (2024). Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes. PROGRESS IN CARDIOVASCULAR DISEASES, 87, 73-82 [10.1016/j.pcad.2024.10.006].

Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes

Foa A.;Bergamaschi L.;Amicone S.;Angeli F.;Armillotta M.;Pizzi C.
2024

Abstract

The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a “red flag” of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis).
2024
Belmonte, M., Foa, A., Paolisso, P., Bergamaschi, L., Gallinoro, E., Polimeni, A., et al. (2024). Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes. PROGRESS IN CARDIOVASCULAR DISEASES, 87, 73-82 [10.1016/j.pcad.2024.10.006].
Belmonte, M.; Foa, A.; Paolisso, P.; Bergamaschi, L.; Gallinoro, E.; Polimeni, A.; Scarsini, R.; Muscoli, S.; Amicone, S.; De Vita, A.; Villano, A.; A...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/999955
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact